Sung-Bae Cho
Algemeen Directeur bij CHOA PHARMACEUTICAL CO., LTD.
Vermogen: 875 295 $ op 30-04-2024
Profiel
Sung-Bae Cho is currently the President, Co-Chief Executive Officer & Director at ChoA Pharmaceutical Co., Ltd.
He previously worked as the Vice President at Medipharm.
Mr. Cho completed his undergraduate degree at Hanyang University.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 31-03-2023 | 750 000 ( 2.42% ) | 875 295 $ | 30-04-2024 |
Actieve functies van Sung-Bae Cho
| Bedrijven | Functie | Begin |
|---|---|---|
| CHOA PHARMACEUTICAL CO., LTD. | Algemeen Directeur | 17-10-2014 |
Eerdere bekende functies van Sung-Bae Cho
| Bedrijven | Functie | Einde |
|---|---|---|
Medipharm
 Medipharm Medical DistributorsDistribution Services Medipharm, founded in 2015, is a cannabis concentrate and derivative product manufacturer based in Seongnam, South Korea. The South Korean company has a good manufacturing practices certified facility with ISO standard-built clean rooms and five primary extraction lines for delivering pure and precision-dosed cannabis products. Medipharm invests in research-driven teams, state-of-the-art technology, and downstream purification methodologies to formulate, develop, process, package, and distribute cannabis extracts and advanced cannabinoid-based products to domestic and international markets. The CEO of the private company is Sung-Hwan Cho. | Corporate Officer/Principal | - |
Opleiding van Sung-Bae Cho
| Hanyang University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| CHOA PHARMACEUTICAL CO., LTD. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Medipharm
Medipharm Medical DistributorsDistribution Services Medipharm, founded in 2015, is a cannabis concentrate and derivative product manufacturer based in Seongnam, South Korea. The South Korean company has a good manufacturing practices certified facility with ISO standard-built clean rooms and five primary extraction lines for delivering pure and precision-dosed cannabis products. Medipharm invests in research-driven teams, state-of-the-art technology, and downstream purification methodologies to formulate, develop, process, package, and distribute cannabis extracts and advanced cannabinoid-based products to domestic and international markets. The CEO of the private company is Sung-Hwan Cho. | Distribution Services |
